A clinical trial in Australia that’s testing the genetic therapy KLN-1010 in people with hard-to-treat multiple myeloma has won regulatory approval to add new…
Myeloma
Today, Jan. 26, is the first day of tax season here in the U.S. Last week, our accountant emailed her annual reminder to collect the…
The other day, I discovered an old, folded road map in the glove compartment. It had faded colors and deep creases. After I spread it…
Treatment with Tecvayli (teclistamab) was better than standard therapies at delaying disease progression and prolonging survival among previously-treated myeloma patients in a Phase…
Here’s a ray of hope from the American Cancer Society (ACS): Its recently released annual Cancer Statistics report noted that the five-year relative cancer…
Yesterday morning, I burned the toast. It wasn’t just a little, either. It was blackened to a crisp and set off the smoke alarm with…
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
We’re nearly two weeks into the new year and I’m wondering, how are your resolutions going? If your answer is, “Not so well,” take heart…
There is a specific kind of silence that occurs only when there is bad news. This type of silence isn’t peaceful or calm. It is…
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body…
Recent Posts
- Early ovarian cancer trial seeking participants to test higher therapy dose
- As a caregiver, I’ve learned to read my mum’s daily forecast
- Short radiation course may ease painful myeloma bone lesions
- Nearly 70% of those given approved myeloma therapy alive 5 years later
- Latest AACR progress report on myeloma is a superpower of good news